Page last updated: 2024-12-07
9-methyl-7-bromoeudistomin d
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
9-methyl-7-bromoeudistomin D: potent inducer of calcium release from sarcoplasmic reticulum of skeletal muscle [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 129958 |
| CHEBI ID | 34514 |
| SCHEMBL ID | 7083487 |
| MeSH ID | M0168619 |
Synonyms (16)
| Synonym |
|---|
| C13748 , |
| 9-methyl-7-bromoeudistomin d |
| mbed |
| 123363-40-6 |
| 5,7-dibromo-9-methylpyrido[3,4-b]indol-6-ol |
| AC1L2WIW , |
| 9h-pyrido(3,4-b)indol-6-ol, 5,7-dibromo-9-methyl- |
| 9-methyl-7-bromoeudistomin-d |
| CHEBI:34514 |
| SCHEMBL7083487 |
| 5,7-dibromo-9-methyl-pyrido[3,4-b]indol-6-ol |
| surecn7083487 |
| DTXSID10153990 |
| AKOS028111022 |
| 9h-pyrido[3,4-b]indol-6-ol, 5,7-dibromo-9-methyl- |
| Q27116124 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response relationship of caffeine-induced inhibition of cAMP-PDEs was not correlated with the stimulation of insulin secretion." | ( Ryanodine receptors of pancreatic beta-cells mediate a distinct context-dependent signal for insulin secretion. Ahmed, M; Bruton, JD; Frame, M; Furman, BL; Islam, MS; Lemmens, R; Persson-Sjögren, S; Pyne, NJ; Shi, CL; Westerblad, H, 2003) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| beta-carbolines | Any pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 11 (73.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||